

## ASX ANNOUNCEMENT

ASX: 1AI | 27 November 2025

### Distribution Agreement Highlights

- **Distribution agreement signed with Dr. Reddy's Laboratories Ltd**
- **First shipment of Capecitabine to Australia expected December 2025**
- **Strategic partnership expands Algorae's commercial footprint**

AI-enabled pharmaceutical company Algorae Pharmaceuticals Ltd (ASX: 1AI) is pleased to announce it has entered into a distribution agreement with global pharmaceutical leader **Dr. Reddy's Laboratories Ltd (NSE: DRREDDY, NYSE: RDY)** to supply the chemotherapy medicine Capecitabine (Capecitabine 500mg Tab) into the Australian market. As per the agreement terms, the first shipment is expected to arrive in December 2025.

Dr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company is committed to providing access to affordable and innovative medicines. The company develops and commercialises active pharmaceutical ingredients, generics, branded generics, biosimilars and consumer health products. Partnering with Dr. Reddy's, a multinational of scale and reputation, provides Algorae with the opportunity to expand its commercial presence and establish a strategic platform for future collaborations.

Algorae Chief Commercial Officer **Mr. Vishal Shah** commented:

*"Our distribution arrangement with Dr. Reddy's for Capecitabine represents Algorae's ongoing focus on oncology product commercialisation and provides the Company with a clear pathway to near-term revenue. We are delighted to enter into an agreement with such a reputable partner and look forward to positioning Algorae for long-term growth and future product collaborations"*

Through its wholly owned subsidiary AlgoraeRx Pty Ltd, the Company has now executed two commercial agreements to complement ongoing Research & Development activities in the oncology sector at the prestigious Peter MacCallum Cancer Centre in Melbourne, Australia. Results from this validation testing are anticipated in Q4 2025.

Algorae continues to progress several commercial initiatives and will update shareholders as these advance.

**Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd**

**END.**

## **Corporate and Media Enquiries**

Mr David Hainsworth

Executive Chairman

E: [investors@algoraepharma.com](mailto:investors@algoraepharma.com)

## **About Algorae Pharmaceuticals**

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development. In parallel, Algorae operates a commercialisation business, AlgoraeRx, that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae collaborates with leading research institutions and industry partners to translate AI-predicted therapies and to expand patient access to high-quality medicines.

Algorae is listed and publicly traded on the Australian Stock Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit [www.algoraepharma.com](http://www.algoraepharma.com) or follow @algoraepharma on X or LinkedIn.

## **Forward-looking Statements**

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.